InsidersTradesSigma
Follow the Intuitive Surgical INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Intuitive Surgical INC has recorded 395 reports. Market capitalisation: €140.2bn. The latest transaction was filed on 21 August 2026 (Cession). Among the most active insiders: Brosius Mark. Every trade is openly available.
395
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€14m
63 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Intuitive Surgical INC Buy (bullish), based on 30 analysts. Average price target: US$478.01.
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,016 of 29,024 companies
61.0
score / 100
Value34
Quality88
FCF yld1.9%
Earn yld2.1%
EV/EBITDA36.9x
ROE17%
Gross mgn66%
Net mgn28%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2026
Declarations395 total
77 shares@ US$396.37Common StockSEC:0002010300-26-000029:0
77 shares@ US$375.57Common StockSEC:0002010300-26-000029:1
77 shares@ US$390.670.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:0
77 shares@ US$394.000.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:1
77 shares@ US$394.260.0000% mcap1.0% of flowCommon StockSEC:0002010300-26-000027:2
10,000 shares@ US$400.000.0028% mcap9.0% of flowCommon StockSEC:0001280628-26-000014:0
400 shares@ US$379.000.0001% mcap8.6% of flowCommon StockSEC:0001781750-26-000006:0
72 shares@ US$393.100.0000% mcap1.6% of flowCommon StockSEC:0001781750-26-000006:1
28 shares@ US$351.000.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000025:1
28 shares@ US$346.830.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000025:0
28 shares@ US$344.000.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000023:0
28 shares@ US$365.580.0000% mcap0.4% of flowCommon StockSEC:0002010300-26-000023:1
28 shares@ US$360.210.0000% mcap0.3% of flowCommon StockSEC:0002010300-26-000023:2
1,910 shares0Common StockSEC:0001519593-26-000012:0
947 shares@ US$411.550.0003% mcap2.4% of flowCommon StockSEC:0001519593-26-000012:1
23 sharesCommon StockSEC:0002010300-26-000021:0
25 sharesCommon StockSEC:0002010300-26-000021:1
23 sharesCommon StockSEC:0002010300-26-000019:1
23 sharesCommon StockSEC:0002010300-26-000019:0
23 sharesCommon StockSEC:0002010300-26-000019:2
18 shares@ US$446.040.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:0
18 shares@ US$439.800.0000% mcap0.5% of flowCommon StockSEC:0002010300-26-000017:1
750 shares0Common StockSEC:0001277620-26-000002:0
531 shares0Common StockSEC:0001249557-26-000002:0
25 of 395 declarations
About Intuitive Surgical INC
Intuitive Surgical Inc. is a flagship U.S. medtech company listed on the NASDAQ in the United States. Founded in 1995 and headquartered in Sunnyvale, California, the company is widely recognized as the pioneer of robotic-assisted minimally invasive surgery. From an investor’s perspective, ISRG is best understood as a platform business: it sells robotic systems, instruments and accessories, and services, creating a meaningful recurring-revenue profile and a sticky installed base in hospitals and ambulatory settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1035267/000103526725000099/a2024_intuitiveannualrepor.pdf?utm_source=openai)) The company’s core franchise is the da Vinci family of surgical robotic systems, complemented by the Ion endoluminal system for lung biopsy and other endoluminal applications. Intuitive serves a broad range of procedures, including urology, gynecology, general surgery, thoracic surgery, colorectal surgery, and selected ENT applications, depending on regulatory approvals in each market. A major strategic step has been the rollout of da Vinci 5, the company’s newest platform generation, which adds software capabilities and real-time surgical insights aimed at improving workflow efficiency and system performance. ([intuitive.com](https://www.intuitive.com/en-us?utm_source=openai)) Competitive positioning remains one of Intuitive’s key strengths. The company is the global leader in surgical robotics, supported by strong brand equity, a large installed base, broad surgeon familiarity, and an ecosystem of training, clinical support, and service that is difficult for competitors to replicate quickly. That leadership has continued to translate into healthy procedure growth in 2025, with management updates highlighting rising worldwide usage across da Vinci and Ion, as well as increasing adoption of da Vinci 5. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-preliminary-fourth-quarter-and-full-year-5?utm_source=openai)) Geographically, Intuitive is a U.S.-based company with a global commercial footprint across North America, Europe, and other developed international markets. Recent milestones have reinforced its innovation pipeline: the FDA expanded da Vinci SP indications in 2025, Intuitive introduced new real-time software features for da Vinci 5, enhanced AI and imaging integration in Ion, and received CE Mark approval for da Vinci 5 in Europe. For equity investors, the combination of technology leadership, recurring revenue, and secular adoption of minimally invasive surgery underpins the long-term thesis. ([isrg.intuitive.com](https://isrg.intuitive.com/news-releases/news-release-details/intuitive-announces-fda-clearance-da-vinci-single-port-transanal?utm_source=openai))
